GENFLEET-B (02595) has issued an announcement stating that the company recently noted several reports concerning a letter sent by Revolution Medicines Inc. ("Rev Med") to a third-party company regarding a dispute over RAS inhibitor patents and trade secrets. The company hereby clarifies and emphasizes that the entities, products, and matters in dispute mentioned in Rev Med's letter are entirely unrelated to GENFLEET. The company's Pan RAS inhibitor, GFH276, possesses completely independent and original intellectual property rights, with no risk of similar infringement or trade secret disputes. GENFLEET has established a comprehensive global patent portfolio for its Pan RAS inhibitor program. A patent covering the compound structure of GFH276 was officially published on March 6, 2025, with an expected protection period lasting until 2044.